I have no doubt that the reason the elite have chosen Monkeys to be the vector of the latest PANDEMIC, is because they believe that the Monkey’s DNA is closest to ours and they very likely have created the virus that can cross over our blood barrier.
Aren’t you at all concerned that so many Monkeys are being brought into our environment? We never had Monkeys in our nation before they started all the BIO LABS. Now there are already areas in our Nation that are overrun with dangerous Monkeys. They can spread like mad. Just as anyone in India what it is like to deal with moneys running loose and running amok.
Why does the public not care that so many Monkeys are being bred and housed here and used for God only knows what kind of experimentation. Have you ever seen the “SECRET OF NIMH”. It is a children’s cartoon movie, but it was an effort to warn us what was happening laboratories. They have been mixing DNA and putting human brain material in all manner of creatures for years… It is no wonder that whales know how to attack boats at their most vulnerable spot putting them out of commission. It is no wonder that we see human type behaviors in rats and cats. It is no wonder that suddenly Apes can talk and elephants can paint. and dolphins are serving in our navy sinking ships and disarming/killing enemies. etc. etc.
PEOPLE WE ARE LIVING IN THE DAYS that are AS IT WAS IN THE DAYS OF NOAH predicted in the BIBLE. Not only are we just partying, eating and drinking and marrying and giving in marriage… WE AM MESSING WITH THE DNA OF ALL LIFE. EXACTLY AS THE FALLEN ANGELS TAUGHT HUMANS TO DO IN THE DAYS OF NOAH. In fact, they had corrupted all flesh except that of NOAH and his family. LET’s NOT LET IT GET THAT FAR AGAIN!
If you don’t find this NEWS upsetting and infuriating… if you don’t see it as any kind of a threat to our health or our environment… you are not using your critical thinking.
spacer
spacer
spacer
spacer
spacer
WHO Director-General Dr Tedros Adhanom Ghebreyesus has determined that the upsurge of mpox in the Democratic Republic of the Congo (DRC) and a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC) under the International Health Regulations (2005) (IHR).
Dr Tedros’s declaration came on the advice of an IHR Emergency Committee of independent experts who met earlier in the day to review data presented by experts from WHO and affected countries. The Committee informed the Director-General that it considers the upsurge of mpox to be a PHEIC, with potential to spread further across countries in Africa and possibly outside the continent.
The Director-General will share the report of the Committee’s meeting and, based on the advice of the Committee, issue temporary recommendations to countries.
In declaring the PHEIC, Dr Tedros said, “The emergence of a new clade of mpox, its rapid spread in eastern DRC, and the reporting of cases in several neighbouring countries are very worrying. On top of outbreaks of other mpox clades in DRC and other countries in Africa, it’s clear that a coordinated international response is needed to stop these outbreaks and save lives.”
WHO Regional Director for Africa Dr Matshidiso Moeti said, “Significant efforts are already underway in close collaboration with communities and governments, with our country teams working on the frontlines to help reinforce measures to curb mpox. With the growing spread of the virus, we’re scaling up further through coordinated international action to support countries bring the outbreaks to an end.”
Committee Chair Professor Dimie Ogoina said, “The current upsurge of mpox in parts of Africa, along with the spread of a new sexually transmissible strain of the monkeypox virus, is an emergency, not only for Africa, but for the entire globe. Mpox, originating in Africa, was neglected there, and later caused a global outbreak in 2022. It is time to act decisively to prevent history from repeating itself.”
This PHEIC determination is the second in two years relating to mpox. Caused by an Orthopoxvirus, mpox was first detected in humans in 1970, in the DRC. The disease is considered endemic to countries in central and west Africa.
In July 2022, the multi-country outbreak of mpox was declared a PHEIC as it spread rapidly via sexual contact across a range of countries where the virus had not been seen before. That PHEIC was declared over in May 2023 after there had been a sustained decline in global cases.
Mpox has been reported in the DRC for more than a decade, and the number of cases reported each year has increased steadily over that period. Last year, reported cases increased significantly, and already the number of cases reported so far this year has exceeded last year’s total, with more than 15 600 cases and 537 deaths.
The emergence last year and rapid spread of a new virus strain in DRC, clade 1b, which appears to be spreading mainly through sexual networks, and its detection in countries neighbouring the DRC is especially concerning, and one of the main reasons for the declaration of the PHEIC.
In the past month, over 100 laboratory-confirmed cases of clade 1b have been reported in four countries neighbouring the DRC that have not reported mpox before: Burundi, Kenya, Rwanda and Uganda. Experts believe the true number of cases to be higher as a large proportion of clinically compatible cases have not been tested.
Several outbreaks of different clades of mpox have occurred in different countries, with different modes of transmission and different levels of risk.
The two vaccines currently in use for mpox are recommended by WHO’s Strategic Advisory Group of Experts on Immunization, and are also approved by WHO-listed national regulatory authorities, as well as by individual countries including Nigeria and the DRC.
Last week, the Director-General triggered the process for Emergency Use Listing for mpox vaccines, which will accelerate vaccine access for lower-income countries which have not yet issued their own national regulatory approval. Emergency Use Listing also enables partners including Gavi and UNICEF to procure vaccines for distribution.
WHO is working with countries and vaccine manufacturers on potential vaccine donations, and coordinating with partners through the interim Medical Countermeasures Network to facilitate equitable access to vaccines, therapeutics, diagnostics and other tools.
WHO anticipates an immediate funding requirement of an initial US$ 15 million to support surveillance, preparedness and response activities. A needs assessment is being undertaken across the three levels of the Organization.
To allow for an immediate scale up, WHO has released US$ 1.45 million from the WHO Contingency Fund for Emergencies and may need to release more in the coming days. The Organization appeals to donors to fund the full extent of needs of the mpox response.
spacer
MONKEY POX |
Mpox in the United States and Around the World: Current Situation
What to know
- There are two kinds of the virus that causes mpox, clade I and clade II. You can’t tell which kind of mpox someone has by looking at them.
- Each clade of the virus has subclades, clade Ia and clade Ib; clade IIb. Outbreaks from the subclades can have different characteristics, like who they affect, how they’re spread, or even how many deaths they cause.
- There are outbreaks of clade I mpox in the Democratic Republic of the Congo (DRC) that began in 2023. The outbreak on the eastern part of the country has spread into neighboring countries in 2024.
- Mpox spreads through close or intimate contact with a person with mpox. This could mean living in close quarters, or it may mean through sexual contact with a person with mpox.
- It may also spread by direct contact with contaminated items and surfaces used by people with mpox.
- In areas that regularly have mpox cases in Western and Central Africa, people can also get mpox from contact with infected wild animals.
- The disease is not known to spread in settings where only respiratory spread is possible – for example, across rooms, in markets or classrooms, etc.
- CDC recommends vaccination with two doses of JYNNEOS for people in the United States at risk of mpox. The vaccine is FDA approved for and expected to protect against both clades and all subclades of mpox.
- CDC is working with public health partners in the United States and throughout Africa to monitor for mpox cases and increase surveillance capacity, in addition to other activities.
- Clade II mpox cases continue to spread at low levels in many countries around the world.
In the United States
- There have been no reported cases of clade I mpox in the United States.
- Clade II mpox is still circulating at low levels.
- Because many cases in areas that regularly have mpox outbreaks have been in children, many people have concerns about the risk of mpox in children in the United States.
- Children have historically gotten mpox in endemic areas in Western and Central Africa often because they have contact with wild animals in those areas that carry the disease then pass it to humans; those humans can then spread mpox to close household contacts. The animals are called “reservoirs.” Animals in the United States do not carry the virus that causes mpox.
- The high number of children with mpox reported in the current DRC outbreak also likely reflects spread within households. Numerous factors probably contribute to this, including crowded households, lack of access to disinfection and hygiene supplies, lack of access to medical care, and malnutrition.
- Based on what we know right now, we don’t expect to see the same sort of risk if mpox were introduced in the United States for several reasons, including different household makeup and size, access to disinfecting products, and improved access to medical care.
- CDC simulated clade I mpox outbreaks resulting from close-contact transmission within and between households (household clusters) in the United States to better understand the potential impact of this transmission route. This modeling included children. The results indicate that close-contact transmission within and between households is unlikely to result in a large number of mpox clade I cases in the United States.
Across the globe
- There are outbreaks of clade I mpox in Central and Eastern Africa. There have been a few cases in people who traveled from that region to other countries, where they got sick.
- Clade I has two subclades, clade Ia and clade Ib.
- In Central Africa, people have gotten clade Ia mpox through contact with infected dead or live wild animals, household transmission, or patient care; a high proportion of cases have been reported in children younger than 15 years of age.
- Subclade Ib was recently identified in eastern DRC and has been spread through intimate and adult sexual contact between different demographics, including heterosexual spread with sex trade workers. So, far clade Ib has a lower case-fatality rate than clade Ia mpox.
- The ongoing global outbreak of clade II mpox has caused more than 100,000 cases in 122 total countries, including 115 countries where mpox was not previously reported. The outbreak is caused by the subclade IIb.
- Historically, only Cameroon in West Africa had cases of both clade I and clade II mpox, but they were seen in different parts of the country. To date, no other country has reported cases due to both clades, with the exception of the recent travel-associated clade I cases in Germany, India, Sweden, Thailand, the United Kingdom, Zambia, and Zimbabwe.
Global mpox cases: data dashboard and map
Data as of: 8-Nov-24
Confirmed* mpox cases since January 1, 2024**
Locations*** with mpox cases since January 1, 2024
** Case data reported in humans to WHO since January 1, 2024, are provided for situational awareness and subject to change. Confirmed cases include those laboratory-confirmed as monkeypox virus and may include cases only confirmed as orthopoxvirus. For more information and additional limitations, see WHO-reported data at 2022-24 Mpox (Monkeypox) Outbreak: Global Trends (shinyapps.io).***Locations include countries, territories, and other areas.
Notes: Case data reported in humans to WHO since January 1, 2024, are provided for situational awareness and subject to change. Confirmed cases include those laboratory-confirmed as monkeypox virus and may include cases only confirmed as orthopoxvirus. For more information and additional limitations, see WHO-reported data at 2022-24 Mpox (Monkeypox) Outbreak: Global Trends (shinyapps.io).
Source: 2022-24 Mpox Outbreak: Global Trends. Geneva: World Health Organization, 2024. Available online: https://worldhealthorg.shinyapps.io/mpx_global/ (last cited: August 27, 2024)
What CDC is doing
In Africa
- CDC and in-country partners across Africa work together on disease surveillance, laboratory capacity-building, strengthening local workforce capacity, case investigation, strengthening case management, infection prevention and control, and vaccine strategy and planning.
- CDC is providing support to governmental, multilateral, and non-governmental public health partners in DRC and around the region.
- CDC is collaborating with governmental and civil society partners in affected countries to collect and analyze case data, and to identify how mpox is spreading.
- CDC trained nearly 100 field epidemiologists in the DRC and continues to provide key support for many who are still working in priority health zones. These CDC-trained epidemiologists are playing a key role in DRC efforts to detect cases, trace and monitor contacts, and increase community awareness of mpox, while also collecting and sending specimens to labs for testing, and training healthcare workers to do the same.
- CDC staff in DRC provide technical assistance and CDC provides funding through cooperative agreements to the DRC Ministry of Health and leading USG implementing partners such as the World Health Organization, AFENET, Gavi and the International Organization for Migration (IOM).
- CDC and USAID are coordinating technical assistance in response to urgent needs identified by national governments and local partners in the areas of laboratory, surveillance, risk communication and community engagement, case management, infection prevention and control, psychosocial support, and vaccine planning.
- The USG is also working closely with several other countries in the region to assist with monitoring the situation as new information becomes available.
In the United States
- CDC works closely with state, tribal, local, and territorial public health departments to provide recommendations for clinical management, diagnosis, and prevention of mpox cases in the U.S.
- CDC continually increases capacity in communities across the United States for early detection of mpox through existing surveillance systems, including wastewater testing.
- CDC raises awareness for healthcare providers, including the latest guidance for considering mpox as a possible diagnosis in certain patients.
- CDC has information and recommendations for members of the public, including those traveling to Central or Eastern Africa: Travel Health Notice and Health Alert Network advisory.
- CDC works with researchers and partner organizations to increase health equity around mpox and ensure that the populations most affected by mpox have access to the mpox vaccine.
- CDC conducts assessments to determine the risks of mpox to the people in the United States.
spacer
A POX TO FINISH THE JOB!
UPDATE ADDED 9/2/24 UPDATE ADDED 9/1/2024 So many questions W.H.O. doesn’t answer. IF you don’t believe by now, you just don’t want to face the truth! Folks, people have been warning about this for YEARS!! And still the sheeple follow mindlessly. Trusting those who have never had a word of truth pass through them. I … Click Here to Read More
WHERE MONKEYPOX CAME FROM.
Zoonoses – WHO | World Health Organization Jul 29, 2020A zoonosis is an infectious disease that has jumped from a non-human animal to humans. Zoonotic pathogens may be bacterial, viral or parasitic, or may involve unconventional agents and can spread to humans through direct contact or through food, water or the environment. They represent a major public … Click Here to Read More